Targeting YAP-dependent MDSC infiltration impairs tumor progression by Guocan Wang et al.
POSTER PRESENTATION Open Access
Targeting YAP-dependent MDSC infiltration
impairs tumor progression
Guocan Wang, Xin Lu, Prasenjit Dey, Pingna Deng, Chia Chin Wu, Shan Jiang, Zhuangna Fang, Kun Zhao,
Ramakrishna Konaparthi, Sujun Hua, Jianhua Zhang, Elsa M Li Ning Tapia, Avnish Kapoor, Neelay Patel,
Zhenglin Guo, Vandhana Ramamoorthy, Trang Tieu, Tim Heffernan, Di Zhao, Xiaoying Shang, Sunada Khadka,
Pingping Hou, Baoli Hu, Qing Chang, Patricia Troncoso, Christopher Logothetis, Mark McArthur, Lynda Chin,
Y Alan Wang, Ronald DePinho
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Background
Myeloid-derived suppressor cells (MDSCs) represent a
phenotypically heterogeneous population of immature
myeloid cells that play a tumor-promoting role by main-
taining a state of immunological anergy and tolerance.
Similar to other solid tumor types, Prostate cancer (PCa)
is characterized by a rich tumor-stroma interaction net-
work that forms the TME. MDSC abundance in the
blood correlates with circulating Prostate Specific Anti-
gen (PSA) levels in PCa patients. MDSCs have been iden-
tified recently as a TME constituent in an indolent PCa
mouse model with conditional Pten deletion, which
antagonized senescence during early tumorigenesis.
However, the molecular signaling mechanisms and their
cellular origins underlying the recruitment of MDSCs are
not well understood and the extent to which MDSCs
facilitate PCa progression has not been determined.
Results
The signaling mechanisms between cancer cells and infil-
trating immune cells of prostate cancer may illuminate
novel therapeutic approaches. Here, utilizing a murine
prostate adenocarcinoma model driven by loss of Pten
and Smad4 (Pb-Cre; PtenL/L;Smad4 L/L), we identify poly-
morphonuclear myeloid-derived suppressor cells
(MDSCs) as the major infiltrating immune cell type and
depletion of MDSCs blocks progression. Employing a
dual cancer cell and host cell reporter prostate cancer
model system (Pb-Cre; PtenL/L;Smad4 L/L;Rosa26-
mTmGL/+), transcriptomic profiling of epithelial and
stromal constituents identified Cxcl5 as a cancer-secreted
chemokine to attract Cxcr2-expressing MDSCs and, cor-
respondingly, pharmacological inhibition of Cxcr2
impeded tumor progression. Integrated analyses identi-
fied hyperactivated Hippo-YAP signaling in driving Cxcl5
upregulation in cancer cells through YAP-TEAD com-
plex and promoting MDSCs recruitment. Clinico-patho-
logical studies reveal upregulation and activation of
YAP1 in a subset of human prostate tumors, and the
YAP1 signature is enriched in these primary prostate
tumor samples with stronger expression of MDSC rele-
vant genes. Together, YAP-driven MDSC recruitment via
heterotypic Cxcl5-Cxcr2 signaling, which promotes pros-
tate tumor progression, reveals effective anti-MDSC ther-
apeutic interventions for advanced prostate cancer.
Significance
This study employs a novel autochthonous prostate can-
cer model to demonstrate a critical role of MDSCs in
tumor progression. In addition, we discover a cancer cell
non-autonomous function of Hippo-YAP pathway in reg-
ulation of Cxcl5, a ligand for Cxcr2 expressing MDSCs.
Pharmacologic elimination of MDSCs or blocking the
heterotypic CxCl5-Cxcr2 signaling circuit elicits robust
anti-tumor responses in vivo and prolongs survival.
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